Multaq Liver Damage and Heart Problem Lawsuits

The lawyers at Saiontz & Kirk are no longer investigating Multaq Lawsuits.  The information on this page is provided for information purposes only.

As a result of the drug maker’s failure to adequately research their medication or warn about the risk of health problems including:

  • Liver Failure
  • Liver Damage
  • Heart Failure
  • Heart Attack
  • Stroke


Multaq (dronedarone) is a Sanofi-Aventis drug approved in July 2009 for treatment of abnormal heart rhythems, knwon as atrial firbillation.

New Multaq cases are no longer being accepted by Saiontz & Kirk, P.A. This page is maintained for informational purposes only.

When Multaq was first released, Sanofi was only allowed to release it with a Risk Evaluation and Mitigation Strategy because it carried a potential increased risk of death for patients with severe heart failure or for individuals who had recently been in the hospital for heart failure.

During the first two years the medication was available, about half a million prescriptions for Multaq were filled in the United States.

It appears that consumers may have been exposed to a risk of serious and potentially life-threatening health problems from Multaq, which were not adequately warned about on the drug label.

In January 2011, the FDA warned that it had received reports of Multaq liver failure, often resulting in the need for a liver transplant. Since then, a number of cases have been reported involving individuals who have experienced liver damage on Multaq.

Sanofi-Aventis has been warned by the FDA for failing to properly report seriuous and unexpected reports of Multaq problems within required time frames.

In July 2011, a Multaq study was suddenly halted after it was determined that users may be facing an increased risk of heart problems. Multaq was deemed too risky for heart patients involved in the study after data suggested side effects of the medication may cause a two-fold increase in the risk of cardiovascular problems, such as heart attacks, stroke and death, among older users with permanent atrial fibrillation.


As a result of Sanofi-Aventis’ failure to provide adequate information about the potential Multaq risks, individuals who suffered liver problems, heart attack, stroke or sudden death may be entitled to financial compensation. Individual injury lawsuits and potential Multaq class action suits are being reviewed by the product liability lawyers at Saiontz & Kirk.

All cases are investigated and handled by our Multaq lawyers under a contingency fee agreement, which means that there are never any out-of-pocket expenses to hire our law firm and pursue a case. Our lawyers are only paid if a recovery is obtained in the Multaq case.

New Multaq cases are no longer being accepted by Saiontz & Kirk, P.A. This page is maintained for informational purposes only.